

## ASX Announcement

### Appendix 3Y – Dr John Cullity

**10 January 2022** – Race Oncology Limited (“Race”) announces that Non-Executive Chairman, Dr John Cullity through controlled entity BioSynergy Partners Pty Ltd, has sold 300,000 Race shares to cover personal and tax commitments. 200,000 of the shares were placed with two long-term Race shareholders via separate on-market crossing transfers. The other 100,000 shares were sold on market between 4–10 January 2022.

Dr John Cullity commented, *“My thanks go to the two long-term shareholders who have taken up additional Race shares. While this sale enables me to take care of some personal obligations, I commit to not selling further Race shares over the next 12 months.”*

An Appendix 3Y, Change of Directors Interest notice follows this announcement.

-ENDS-

#### About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene. Learn more at [www.raceoncology.com](http://www.raceoncology.com).

#### Release authorised by:

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

#### Media contact:

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Race Oncology Limited</b>
<b>ABN</b>	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr John Cullity</b>
<b>Date of last notice</b>	<b>12 November 2021</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	1. Craganorig Holdings, LLC – director related entity 2. Biosynergy Partners Pty Ltd – director related entity
<b>Date of change</b>	4 – 10 January 2022
<b>No. of securities held prior to change</b>	1. 2,000,000 Ordinary Shares 2. 6,402,194 Ordinary Shares 189,394 Options exercisable at \$4.50, expiring 16/5/2022
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	-
<b>Number disposed</b>	2. 300,000
<b>Value/Consideration includes brokerage/gst</b> Note: If consideration is non-cash, provide details and estimated valuation	\$995,174.48

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	1. 2,000,000 Ordinary Shares 2. 6,102,194 Ordinary Shares 189,394 Options exercisable at \$4.50, expiring 16/5/2022
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sales and crossings.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.